457 The basket trial of KY100001K uses IDH mutation as the core enrollment criterion, overcoming tumor tissue-of-origin constraints to efficiently evaluate its efficacy and safety across multiple cancer types, thereby accelerating the precise development of rare molecular subtypes and providing a rationale for pancancer applications
Nausea, jaundice, dark urine, pale stool, severe abdominal pain, confusion, swelling or rapidly worsening fatigue require medical evaluation rather than more supplements or fasting
The research behind supplements for hair loss is limited, with many studies conducted by the product manufacturers, explains Salkey
The compound was patented (US 8,236,761) and discussed in academic publications in the early 2010s
Lupus and Epstein-Barr